Karbis (Candesartan Cilexetil)

Candesartan cilexetil is converted to candesartan, which selectively blocks the angiotensin II type 1 (AT1) receptor. This inhibition prevents vasoconstriction and aldosterone release, leading to vessel relaxation, lower peripheral resistance and reduced blood pressure.

The appropriate dose of Karbis is determined by the prescribing healthcare professional based on the individual’s blood pressure, kidney function and other clinical factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of candesartan cilexetil in pregnancy has not been established, and it is generally avoided because of potential fetal harm. Limited data exist for breastfeeding; the decision should be made by a physician weighing benefits and risks.

To request Karbis, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with ACE inhibitors, candesartan (an ARB) provides similar blood‑pressure reduction but is less likely to cause cough. Unlike calcium‑channel blockers, it directly targets the renin‑angiotensin system, offering additional renal‑protective benefits in certain patients.

Karbis should be stored at room temperature, below 25 °C, in its original packaging. Keep the tablets away from moisture, heat and direct sunlight to maintain stability and potency.

Karbis is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious risks include angioedema, severe hypotension, hyperkalemia and acute kidney injury. Patients should seek immediate medical attention if they experience swelling of the face or throat, dizziness, rapid weight gain, or significant changes in urine output.

Karbis is contraindicated in patients with known hypersensitivity to candesartan or any component of the formulation, in those with severe hepatic impairment, and in individuals who are pregnant. Caution is also advised for patients with bilateral renal artery stenosis.